| ID | 1135 |
| Name of the vaccine | Mencevax ACWY |
| Microbe | Bacteria |
| Disease name | Meningococcal disease |
| Name of bacteria | Neisseria meningitidis |
| Type of vaccine | Subunit |
| Nucleic acid content | DNA |
| Age | Over 2 years |
| Description of the vaccine | Meningococcus serogroup A, C, W-135 and Y vaccine. |
| Name of the manufacturer | GlaxoSmithKline Biologicals |
| Name of the manufacturing country | Belgium |
| Year of manufacture | NA |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-negative diplococcus. |
| Efficacy | Vaccine effectiveness against serogroup A and W-135 was 95.8%. |
| Vaccine formulation | Powder and diluent for solution for injection. |
| Dosage | Single dose (0.5 mL).
Children who were aged under 5 years should be revaccinated every 2-3 years (if high risk). |
| Mechanism of action | Induces bactericidal antibodies against meningococci of the serogroups A, C, W-135 and Y. |
| Route of administration | Subcutaneous |
| Indications | Recommended for people at risk and those living in closed communities and contacts of patients with disease. |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | Irritability, drowsiness, headache, pain and redness at the injection site, fatigue. |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.fda.moph.go.th/sites/drug/Summary/2C_5_53_B_Mencevax%20ACWY.pdf |
| Other name | NA |
| Additional Links | NA
|